OSLO, Norway — Thinfilm, a maker of printed electronics and smart systems, alongside Ypsomed, announced a new partnership that looks to use Thinfilm’s technology in YpsoMate auto-injectors.
Thinfilm’s NFC OpenSense tags are thin labels that can tell whether the injector has been used or not, and can send information about the injector’s state to a smartphone. This allows patients who use YpsoMate Smart injectors for chronic conditions to see their use history — information that is also useful to their doctors for tracking adherence.
“As a leader in innovation and quality, Ypsomed is constantly looking for new ways to improve its product platform offering,” YpsoMed CEO Simon Michel said. “We believe Thinfilm’s NFC OpenSense can be of significant value to YpsoMate users across the globe, and we look forward to leveraging this next-generation technology to help improve patient adherence.”
YpsoMed is investing $51.2 million in developing next-generation injection and infusion systems.
“Ypsomed is at the forefront of self-medication delivery systems, and it’s clear that a focus on user-friendly products and the patient experience has played a key role in their success,” Davor Sutija, Thinfilm’s CEO, said. “We’re pleased to be working with Ypsomed and look forward to helping them connect YpsoMate Smart to the digital world.”